AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2685045 — intervention group
Group type: COMPARATOR
Intervention: Untailored treatment (stimulus control therapy)
Number of subjects: 0
Study 30053853 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwifery group practice (MGP) care
Number of subjects: 115
Study 30053853 — intervention group
Group type: COMPARATOR
Intervention: Standard hospital maternity care (SC)
Number of subjects: 115
Study 28497700 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused intention meditation by biofield practitioners
Number of subjects: 286
Study 28497700 — intervention group
Group type: COMPARATOR
Intervention: Control group (blinded operator selected water samples)
Number of subjects: 286
Study 25572279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmare® treatment (up to 10 sessions)
Number of subjects: 30
Study 25572279 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (non-therapeutic threshold)
Number of subjects: 30
Study 25572279 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmare® treatment
Number of subjects: 30
Study 25572279 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 30
Study 23363640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 585
Study 23363640 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 585
Study 23363640 — intervention group
Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 585
Study 23363640 — intervention group
Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 585
Study 21490695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (2 g) and E (800 IU)
Number of subjects: 39
Study 21490695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18465470 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor stress (CPS)
Number of subjects: 80
Study 18465470 — intervention group
Group type: COMPARATOR
Intervention: Control procedure
Number of subjects: 80
Study 16183188 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (GnRH‐ant)
Number of subjects: 60
Study 16183188 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRH‐a)
Number of subjects: 60
Study 15169798 — intervention group
Group type: EXPERIMENTAL
Intervention: Four vaccinations with fowlpox‐PSA (rF‐PSA)
Number of subjects: 64
Study 15169798 — intervention group
Group type: EXPERIMENTAL
Intervention: Three rF‐PSA vaccines followed by one vaccinia‐PSA (rV‐PSA) vaccine
Number of subjects: 64
Study 15169798 — intervention group
Group type: EXPERIMENTAL
Intervention: One rV‐PSA vaccine followed by three rF‐PSA vaccines
Number of subjects: 64
Study 15169798 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with poxviruses expressing PSA
Number of subjects: 64
Study 11719300 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-min exercise session
Number of subjects: 29
Study 11719300 — intervention group
Group type: COMPARATOR
Intervention: Video control condition (information about exercise and cholesterol)
Number of subjects: 29
Study 9233107 — intervention group
Group type: EXPERIMENTAL
Intervention: ParaGraph
Number of subjects: 40
Study 9233107 — intervention group
Group type: COMPARATOR
Intervention: Timed-dose
Number of subjects: 40
Study 8425810 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical paromomycin treatment
Number of subjects: 91
Study 8425810 — intervention group
Group type: COMPARATOR
Intervention: Untreated (control group)
Number of subjects: 91
Study 3306289 — intervention group
Group type: EXPERIMENTAL
Intervention: Org OD 14
Number of subjects: 60
Study 3306289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 30356343 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracervical injection of 0.25% bupivacaine with epinephrine
Number of subjects: 132
Study 30356343 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 mL normal saline)
Number of subjects: 132
Study 27158956 — intervention group
Group type: EXPERIMENTAL
Intervention: SHIELD program (team-based health promotion program)
Number of subjects: 0
Study 27158956 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 24731118 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐TOKE program
Number of subjects: 317
Study 24731118 — intervention group
Group type: COMPARATOR
Intervention: assessment‐only control
Number of subjects: 317
Study 21951314 — intervention group
Group type: EXPERIMENTAL
Intervention: SB‐705498 (TRPV1 blocker) administered via nasal lavage 2 minutes before each allergen challenge.
Number of subjects: 0
Study 21951314 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study 20162717 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning arm (8:00-10:00 AM)
Number of subjects: 229
Study 20162717 — intervention group
Group type: COMPARATOR
Intervention: Evening arm (6:00-8:00 PM)
Number of subjects: 229
Study 20162717 — intervention group
Group type: EXPERIMENTAL
Intervention: Other radiation-induced toxicity in morning arm
Number of subjects: 229
Study 20162717 — intervention group
Group type: COMPARATOR
Intervention: Other radiation-induced toxicity in evening arm
Number of subjects: 229
Study 20162717 — intervention group
Group type: EXPERIMENTAL
Intervention: Response to radiation in morning arm
Number of subjects: 229
Study 20162717 — intervention group
Group type: COMPARATOR
Intervention: Response to radiation in evening arm
Number of subjects: 229
Study 19253509 — intervention group
Group type: EXPERIMENTAL
Intervention: nsNIMV
Number of subjects: 48
Study 19253509 — intervention group
Group type: COMPARATOR
Intervention: NCPAP
Number of subjects: 48
Study 16192763 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen
Number of subjects: 13
Study 16192763 — intervention group
Group type: EXPERIMENTAL
Intervention: 22.5 mg/kg acetaminophen
Number of subjects: 13
Study 16192763 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg acetaminophen
Number of subjects: 13
Study 16192763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 16192763 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (all doses)
Number of subjects: 13
Study 16192763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 13
Study 12736839 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for 6 months, three times a week, with running at 85‐120% of the lactate anaerobic threshold (LT)
Number of subjects: 18
Study 12736839 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for 6 months
Number of subjects: 18
Study 12736839 — intervention group
Group type: COMPARATOR
Intervention: Untrained
Number of subjects: 18
Study 12736839 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepubertal twins
Number of subjects: 18
Study 12736839 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubertal twins
Number of subjects: 18
Study 11321284 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 291
Study 11321284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 291
Study 9288701 — intervention group
Group type: EXPERIMENTAL
Intervention: Estraderm MX 50 (0.05 mg estradiol per day)
Number of subjects: 109
Study 9288701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study 7506163 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100mg twice daily)
Number of subjects: 60
Study 7506163 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250mg twice daily)
Number of subjects: 60
Study 3828183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% 2‐chloroprocaine 23 ml administered in head-up position
Number of subjects: 50
Study 3828183 — intervention group
Group type: COMPARATOR
Intervention: 3% 2‐chloroprocaine 23 ml administered in supine position
Number of subjects: 50
Study 29885026 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered exercise therapy
Number of subjects: 8
Study 29885026 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered care
Number of subjects: 8
Study 28989140 — intervention group
Group type: EXPERIMENTAL
Intervention: Superelastic NiTi arch wires
Number of subjects: 45
Study 28989140 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-activated NiTi arch wires
Number of subjects: 45
Study 28989140 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study 26280247 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill strategy (containing a statin, antiplatelet agent, and two blood-pressure-lowering medications)
Number of subjects: 623
Study 26280247 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 623
Study 26280247 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypill strategy
Number of subjects: 623
Study 24074738 — intervention group
Group type: EXPERIMENTAL
Intervention: D-aspartic acid (D-ASP) supplementation
Number of subjects: 30
Study 24074738 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21823422 — intervention group
Group type: EXPERIMENTAL
Intervention: Tangzu Yuyang Ointment (TYO) plus Standard Wound Therapy (SWT)
Number of subjects: 57
Study 21823422 — intervention group
Group type: COMPARATOR
Intervention: Standard Wound Therapy (SWT)
Number of subjects: 57
Study 19923205 — intervention group
Group type: EXPERIMENTAL
Intervention: Early feedback of a public report card on baseline performance (January 2004)
Number of subjects: 86
Study 19923205 — intervention group
Group type: COMPARATOR
Intervention: Delayed feedback of a public report card on baseline performance (September 2005)
Number of subjects: 86
Study 17368881 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) supplementation (2.2 g daily for 8 weeks)
Number of subjects: 0
Study 17368881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14687104 — intervention group
Group type: EXPERIMENTAL
Intervention: New drug administration system
Number of subjects: 30
Study 14687104 — intervention group
Group type: COMPARATOR
Intervention: Conventional methods
Number of subjects: 30
Study 11150936 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment
Number of subjects: 45
Study 11150936 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessment
Number of subjects: 45
Study 11150936 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 45
Study 9745973 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride, dosage and duration not specified
Number of subjects: 0
Study 9745973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7818196 — intervention group
Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g) combined with nalbuphine hydrochloride (10 mg)
Number of subjects: 152
Study 7818196 — intervention group
Group type: COMPARATOR
Intervention: Nalbuphine hydrochloride (20 mg)
Number of subjects: 152
Study 2898717 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 micrograms of SMS
Number of subjects: 10
Study 2898717 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of SMS
Number of subjects: 10
Study 2898717 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of SMS
Number of subjects: 10
Study 2898717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31980022 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaxseed powder (30 g/day) plus lifestyle modification
Number of subjects: 41
Study 31980022 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification
Number of subjects: 41
Study 30895611 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (400 mg, three times per day for 7 days)
Number of subjects: 90
Study 30895611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaginal tablet (nystatin 100,000 U, diiodohydroxyquin 100 mg, benzalkonium chloride 7 mg, once daily for 7 days)
Number of subjects: 90
Study 30895611 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole
Number of subjects: 90
Study 30895611 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vaginal tablet
Number of subjects: 90
Study 28554914 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective + momentary assessment (Edinburgh Postnatal Depression Scale + five momentary and two contextual questions)
Number of subjects: 0
Study 28554914 — intervention group
Group type: COMPARATOR
Intervention: Retrospective assessment (Edinburgh Postnatal Depression Scale only)
Number of subjects: 0
Study 28554914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both assessment strategies
Number of subjects: 0
Study 28554914 — intervention group
Group type: EXPERIMENTAL
Intervention: Momentary assessments
Number of subjects: 0
Study 28554914 — intervention group
Group type: EXPERIMENTAL
Intervention: App usage
Number of subjects: 0
Study 25602854 — intervention group
Group type: EXPERIMENTAL
Intervention: CMR
Number of subjects: 60
Study 25602854 — intervention group
Group type: COMPARATOR
Intervention: Sham CMR
Number of subjects: 60
Study 23128968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice a day plus aspirin 100 mg a day
Number of subjects: 203
Study 23128968 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus aspirin 100 mg a day
Number of subjects: 203
Study 21551248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung age‐based motivational strategy
Number of subjects: 67
Study 21551248 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 67
Study 21551248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung age interaction with intervention strategy
Number of subjects: 67
Study 19388074 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted care bundle consisting of medication counseling/reconciliation by a clinical pharmacist, condition specific education/enhanced discharge planning by a care coordinator, and phone follow-up.
Number of subjects: 41
Study 19388074 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 41
Study 19388074 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted care bundle.
Number of subjects: 41
Study 16687453 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (audiovisual presentation)
Number of subjects: 90
Study 16687453 — intervention group
Group type: COMPARATOR
Intervention: Group A (verbal presentation)
Number of subjects: 90
Study 16687453 — intervention group
Group type: COMPARATOR
Intervention: Group B (diagrams with verbal presentation)
Number of subjects: 90
Study 15282063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilmenidine (1 mg)
Number of subjects: 20
Study 15282063 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11224782 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgical tracheostomy
Number of subjects: 164
Study 11224782 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopically guided percutaneous dilational tracheotomy
Number of subjects: 164
Study 9402818 — intervention group
Group type: EXPERIMENTAL
Intervention: High-speed, high-resolution thermography
Number of subjects: 20
Study 9402818 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (normal subjects)
Number of subjects: 20
Study 9402818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (normal blinking vs keeping eyes open after closing)
Number of subjects: 20
Study 8527004 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimuli (tones at 70 dB SPL, oddball paradigm with 1.5K vs. 1K tones)
Number of subjects: 50
Study 8527004 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual stimuli (2.3 cpd sinusoidal grating patterns, oddball paradigm with oblique vs. vertical orientation)
Number of subjects: 50
Study 2214590 — intervention group
Group type: EXPERIMENTAL
Intervention: HM + HMP
Number of subjects: 25
Study 2214590 — intervention group
Group type: COMPARATOR
Intervention: HM + PH
Number of subjects: 25
Study 308770 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensory-stimulating treatment for eight weeks
Number of subjects: 7
Study 308770 — intervention group
Group type: COMPARATOR
Intervention: Sedentary activities for eight weeks (Control)
Number of subjects: 7
Study 30777844 — intervention group
Group type: EXPERIMENTAL
Intervention: Go‐breath app with alarm function (test group)
Number of subjects: 44
Study 30777844 — intervention group
Group type: COMPARATOR
Intervention: Go‐breath app without alarm function (control group)
Number of subjects: 44
Study 30777844 — intervention group
Group type: EXPERIMENTAL
Intervention: Go‐breath app (both groups)
Number of subjects: 44
Study 28753384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m2 (C20)
Number of subjects: 1168
Study 28753384 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m2 (C25)
Number of subjects: 1168
Study 28753384 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2 (D75)
Number of subjects: 1168
Study 26017725 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 20
Study 26017725 — intervention group
Group type: COMPARATOR
Intervention: Control group (no physical rehabilitation)
Number of subjects: 20
Study 24574930 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group with psychiatrist as 'friend'
Number of subjects: 60
Study 24574930 — intervention group
Group type: EXPERIMENTAL
Intervention: Facebook group without psychiatrist as 'friend'
Number of subjects: 60
Study 24574930 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Facebook use)
Number of subjects: 60
Study 22743344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibre post insertion within composite build‐up before cementation of indirect composite onlay restorations
Number of subjects: 0
Study 22743344 — intervention group
Group type: COMPARATOR
Intervention: No fibre post insertion
Number of subjects: 0
Study 20142279 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention novel (describes an overweight girl who discovers improved health and self‐efficacy)
Number of subjects: 81
Study 20142279 — intervention group
Group type: COMPARATOR
Intervention: Control novel
Number of subjects: 81
Study 20142279 — intervention group
Group type: EXPERIMENTAL
Intervention: Either book (intervention or control)
Number of subjects: 81
Study 17610525 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal and written information in Vietnamese
Number of subjects: 95
Study 17610525 — intervention group
Group type: COMPARATOR
Intervention: Routine verbal counselling in English
Number of subjects: 95
Study 15625211 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine + Risperidone (up to 6 mg/day)
Number of subjects: 40
Study 15625211 — intervention group
Group type: COMPARATOR
Intervention: Clozapine + Placebo
Number of subjects: 40
Study 12169075 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin-mineral supplementation
Number of subjects: 652
Study 12169075 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplementation (200 mg)
Number of subjects: 652
Study 12169075 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 652
Study 10440514 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent hemodialysis (HD) - one 4‐h session and Kt/V > or = 1
Number of subjects: 12
Study 10440514 — intervention group
Group type: COMPARATOR
Intervention: Continuous veno‐venous hemofiltration (CVVH) - one 24‐h session and Kt/V > or = 1
Number of subjects: 12
Study 8723585 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa (150 IU/kg subcutaneously on alternate days; six doses)
Number of subjects: 0
Study 8723585 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa combined with normovolemic hemodilution (NVHD)
Number of subjects: 0
Study 8723585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2054690 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg intramuscularly
Number of subjects: 60
Study 2054690 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 15 mg intramuscularly
Number of subjects: 60
Study 6338998 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichloracetic acid (50%) and podophyllin (25%)
Number of subjects: 73
Study 6338998 — intervention group
Group type: COMPARATOR
Intervention: Podophyllin (25%) alone
Number of subjects: 73
Study 31825024 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral health education sessions delivered by trained schoolteachers
Number of subjects: 435
Study 31825024 — intervention group
Group type: COMPARATOR
Intervention: Control group (no extra oral health education)
Number of subjects: 435
Study 28120629 — intervention group
Group type: EXPERIMENTAL
Intervention: ropinirole PR 8 mg/day
Number of subjects: 0
Study 28120629 — intervention group
Group type: EXPERIMENTAL
Intervention: ropinirole PR 12 mg/day
Number of subjects: 0
Study 28120629 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 25827078 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous suture only without subcuticular skin suture (case group, n=68)
Number of subjects: 138
Study 25827078 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous suture and subcuticular skin suture (control group, n=70)
Number of subjects: 138
Study 23873992 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (early neonatal mortality)
Number of subjects: 0
Study 23873992 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (late neonatal mortality)
Number of subjects: 0
Study 23873992 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological factors (early neonatal mortality)
Number of subjects: 0
Study 23873992 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors (late neonatal mortality)
Number of subjects: 0
Study 21106341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline and dextran (HSD)
Number of subjects: 113
Study 21106341 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 113
Study 19249945 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole (0.25-6 mg)
Number of subjects: 1679
Study 19249945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1679
Study 16752943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate 4 mmol/L
Number of subjects: 12
Study 16752943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate 8 mmol/L
Number of subjects: 12
Study 16752943 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexylaminolevulinate 16 mmol/L
Number of subjects: 12